AstraZeneca PLC (Mexico) Insiders
AZNN Stock | MXN 1,384 6.50 0.47% |
AstraZeneca PLC employs about 48 people. The company is managed by 30 executives with a total tenure of roughly 224 years, averaging almost 7.0 years of service per executive, having 1.6 employees per reported executive. Break down of AstraZeneca PLC's management performance can provide insight into the company performance.
Pascal Soriot CEO CEO, Executive Director and Member of Disclosure Committee |
Leif Johansson Chairman Non-Executive Independent Chairman of the Board |
AstraZeneca |
AstraZeneca PLC Management Team Effectiveness
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.AstraZeneca PLC Workforce Comparison
AstraZeneca PLC is rated second in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is presently estimated at about 219. AstraZeneca PLC totals roughly 48.0 in number of employees claiming about 22% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19. AstraZeneca PLC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AstraZeneca PLC Price Series Summation is a cross summation of AstraZeneca PLC price series and its benchmark/peer.
AstraZeneca PLC Notable Stakeholders
An AstraZeneca PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AstraZeneca PLC often face trade-offs trying to please all of them. AstraZeneca PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AstraZeneca PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal Soriot | CEO, Executive Director and Member of Disclosure Committee | Profile | |
Leif Johansson | Non-Executive Independent Chairman of the Board | Profile | |
Jose Baselga | Executive Vice President - Research & Development Oncology | Profile | |
Katarina Ageborg | Executive Vice President - Sustainability, Chief Compliance Officer | Profile | |
Fiona Cicconi | Executive Vice President - Human Resources | Profile | |
Leon Wang | Executive Vice President - International and China President | Profile | |
Pam Cheng | Executive Vice-President of Operations and Information Technology | Profile | |
Ruud Dobber | Executive Vice President, BioPharmaceuticals Business | Profile | |
David Fredrickson | Executive Vice-President Global Head Oncology Business Unit | Profile | |
Menelas Pangalos | Executive Vice President - Research & Development BioPharmaceuticals | Profile | |
Iskra Reic | Executive Vice President - Europe and Canada | Profile | |
Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
Sherilyn McCoy | Non-Executive Independent Director | Profile | |
Genevieve Berger | Non-Executive Independent Director | Profile | |
Nazneen Rahman | Non-Executive Independent Director | Profile | |
Tony Mok | Non-Executive Independent Director | Profile | |
Deborah DiSanzo | Non-Executive Independent Director | Profile | |
Michel Demare | Non-Executive Independent Director | Profile | |
Graham Chipchase | Senior Non-Executive Independent Director | Profile | |
Philip Broadley | Non-Executive Independent Director | Profile | |
Marcus Wallenberg | Non-Executive Director | Profile | |
Deborah Eldracher | Non-Executive Independent Director | Profile | |
Euan Ashley | Non-Executive Director | Profile | |
Chris Sheldon | Head Relations | Profile | |
Adrian Kemp | Company Secretary | Profile | |
Diana Layfield | Non-Executive Director | Profile | |
MBA DVM | CEO Director | Profile | |
Aradhana MD | CFO Director | Profile | |
Jeffrey Pott | General Counsel | Profile | |
Gonzalo Vina | Head Relations | Profile |
About AstraZeneca PLC Management Performance
The success or failure of an entity such as AstraZeneca PLC often depends on how effective the management is. AstraZeneca PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AstraZeneca management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AstraZeneca management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 76100 people.
Please note, the imprecision that can be found in AstraZeneca PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AstraZeneca PLC. Check AstraZeneca PLC's Beneish M Score to see the likelihood of AstraZeneca PLC's management manipulating its earnings.
AstraZeneca PLC Workforce Analysis
Traditionally, organizations such as AstraZeneca PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AstraZeneca PLC within its industry.AstraZeneca PLC Manpower Efficiency
Return on AstraZeneca PLC Manpower
Revenue Per Employee | 924M | |
Revenue Per Executive | 1.5B | |
Net Income Per Employee | 68.5M | |
Net Income Per Executive | 109.6M |
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.